Canadian Cardiovascular Society Awarded $1.4M to Continue Important National Study of COVID-19 and mRNA Vaccines
June 7, 2024
New funding from the Public Health Agency of Canada (PHAC) will enable top Canadian cardiology...
CCS News COVID-19 MYCOVACC![](https://ccs.ca/wp-content/uploads/2024/06/MYCOVACC-News-Release-June-2024-EN.png)
Introducing CCS’s NEW Cardiorenal Pocket Guide
June 2, 2023
The Cardiorenal Risk Reduction in Adults Pocket Guide is now here! Pocket Guides are our most...
Cardiorenal Guidelines Pocket Guides![](https://ccs.ca/wp-content/uploads/2023/05/CCS_Pocket_Guide_Cardiorenal_final_Page_01.png)
Two classes of glucose-lowering drugs reduce risk of heart failure, kidney complications and death – even in patients without type 2 diabetes
September 30, 2022
New Cardiorenal Protection Guideline urges use of GLP-1RA and SGLT2i drugs to save lives; as many as...
Cardiorenal Guidelines